Organigram's entry into the German cannabis market through a supply agreement with Sanity Group expands its international market presence, which is likely to have a positive impact on its stock price in the short term. The company already services medical patients in Israel and Australia, and adding Germany to its list of markets increases its potential for revenue growth.